Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Acquired by Investment Partners LTD.

Investment Partners LTD. boosted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,095 shares of the medical equipment provider’s stock after purchasing an additional 53 shares during the period. Investment Partners LTD.’s holdings in Intuitive Surgical were worth $369,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ISRG. Addison Advisors LLC grew its holdings in Intuitive Surgical by 52.5% during the 4th quarter. Addison Advisors LLC now owns 311 shares of the medical equipment provider’s stock worth $105,000 after acquiring an additional 107 shares in the last quarter. Gilliland Jeter Wealth Management LLC acquired a new position in Intuitive Surgical during the 4th quarter worth $1,670,000. Golden State Equity Partners grew its holdings in Intuitive Surgical by 19.7% during the 4th quarter. Golden State Equity Partners now owns 1,454 shares of the medical equipment provider’s stock worth $491,000 after acquiring an additional 239 shares in the last quarter. Cornerstone Capital Inc. grew its holdings in Intuitive Surgical by 0.3% during the 4th quarter. Cornerstone Capital Inc. now owns 13,261 shares of the medical equipment provider’s stock worth $4,474,000 after acquiring an additional 45 shares in the last quarter. Finally, Kovack Advisors Inc. grew its holdings in Intuitive Surgical by 29.2% during the 4th quarter. Kovack Advisors Inc. now owns 1,350 shares of the medical equipment provider’s stock worth $455,000 after acquiring an additional 305 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Robert W. Baird decreased their price objective on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a report on Friday, April 19th. Truist Financial raised their price target on shares of Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 24th. Citigroup raised their price target on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Jefferies Financial Group raised their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. Finally, Stifel Nicolaus raised their price target on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $396.17.

Intuitive Surgical Stock Performance

Shares of ISRG stock traded up $2.21 during midday trading on Friday, reaching $375.33. 927,845 shares of the company were exchanged, compared to its average volume of 1,564,565. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $403.76. The company has a market cap of $133.13 billion, a P/E ratio of 67.75, a PEG ratio of 4.82 and a beta of 1.36. The company’s 50 day moving average price is $386.19 and its two-hundred day moving average price is $345.95.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same period in the previous year, the firm earned $1.00 EPS. Intuitive Surgical’s revenue was up 11.5% on a year-over-year basis. As a group, sell-side analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Robert Desantis sold 20,296 shares of Intuitive Surgical stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $393.80, for a total value of $7,992,564.80. Following the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,168,656.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Myriam Curet sold 5,318 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total value of $1,971,169.88. Following the transaction, the executive vice president now owns 298 shares of the company’s stock, valued at approximately $110,456.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Robert Desantis sold 20,296 shares of Intuitive Surgical stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the completion of the transaction, the executive vice president now directly owns 5,507 shares in the company, valued at approximately $2,168,656.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 249,418 shares of company stock worth $96,300,959. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.